You are here: Industry Insights > Biohaven

News List

Biohaven Doses First Subject in Bioequivalence Study with BHV-0223 americanpharmaceuticacreview
November 07, 2017
Biohaven is developing BHV-0223, a sublingual formulation of riluzole, as a potential treatment for patients with Amyotrophic Lateral Sclerosis (ALS).
Biohaven Reports Second Quarter 2017 Results americanpharmaceuticalreview
August 15, 2017
Biohaven Pharmaceutical reported financial results for the quarter ended June 30, 2017.
Biohaven Completes Randomization in Phase 2/3 Trial in Spinocerebellar Ataxia americanpharmaceuticalreview
August 08, 2017
Biohaven Pharmaceutical has commenced dosing of all 141 randomized patients with spinocerebellar ataxia (SCA) in its Phase 2/3 trial of trigriluzole (previously known as BHV-4157). Trigriluzole has received both Orphan Drug Designation and Fast Track Desi
Biohaven's Trigriluzole Receives Fast Track Designation from FDA americanpharmaceuticalreview
May 16, 2017
Biohaven Pharmaceutical Holding Company announced the U.S. Food and Drug Administration (FDA) has granted the company Fast Track Designation for Biohaven's product candidate trigriluzole (BHV-4157) for the potential treatment of Spinocerebellar Ataxia (SC

Previous page 1 2 3 4 Next page